Contribute Try STAT+ Today

MONTEGO BAY, Jamaica — The drug manufacturer MannKind has been burning through millions of dollars each month. It only has 3,000 patients taking its sole product, an inhalable form of insulin. It recently said it doesn’t have enough cash to get to the end of this year.

So why, then, is the company sponsoring a reality TV show filmed here in this tropical resort town?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Tropical resort? Contract signing? So much happy horse sh*t. These T2s have already violated their own contracts with their bodies by allowing themselves to tip the scales north of BMI 35 fron a lifetime of gluttony. As a diabetic my insurance covers 10 HOURS of diabetes education. But it is delivered in a sterile classroom, drinking complimentary bottles of zero calorie water instead of watching TV from a tropical island while getting in the mood by secretly sipping pina coladas loaded with sugar. These “contracts” are a gimmick, like the ones the junkies sign with their pain med doc aka dope dealer with a medical license.

  • Absolutely disgusting reporting aimed at minimizing what this company has been able to accomplish and the patients that have come to depend on this truly innovative diabetes medicine. Why spend time on ONLY the negative and not even mention how patients are reporting life best A1C numbers while significantly improving their daily lives through inhaled insulin. Very pathetic, Rebecca.

  • Very well said, i wish them well also. This wanna be reporter seems to have it out for the show and the product. I found this very sad, so many people benefit from Afrezza and if they want to sponsor something to help get the word out so what, big pharma spend billions to market and this small company is trying to compete, whats wrong with that.

  • Inhalable insulin, even if no better medically than injected, would be a TREMENDOUS benefit to many people (and would get some people to be compliant who would NOT be otherwise) . Wishing them well . . . it would be a shame to see something so beneficial die on the vine …

Comments are closed.